BANAGALORE, May 5 (Reuters) - Shares of InterMune Inc crashed 78 percent after U.S. health regulators declined to approve its lung drug, raising doubts about the drug's future. Sign up here. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback